weight loss (Phase 2/3 peak) | ~15% | ~22% | ~24% | | FDA Status | Approved (Wegovy, Ozempic) | Approved (Zepbound, Mounjaro) | Phase 3 (2026) | | Dosing frequency | Weekly | Weekly | Weekly | The additional glucagon receptor agonism is believed to be responsible for retatrutide's greater metabolic rate increase and enhanced fat oxidation compared to dual agonists
Medical Leadership & Advocacy: Past president of the Clark County Medical Society and current President-Elect of the Nevada State Medical Association, Dr
Taking the time to ask thoughtful questions during your consultation can help you make a more informed decision and give you greater confidence moving forward
SaunaLife G6 Shipping Taking Delivery of Your Prebuilt Sauna The size of SaunaLife G6 requires flat-bed truck delivery by special appointment
Meet our latest innovation, Restore Body Protection PDA, a potent blend featuring Pentadecapeptide Arginate, an exceptional sequence of 15 amino acids
Peptide therapy is popular for its relatively low side effects